Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752258 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows
A Phase 3 study, sponsored by Mentor Worldwide.
- Completed
- Registry status
- Phase 3
- Development phase
- 576
- Enrollment target
NCT00752258 is a Phase 3 study that has completed, run by Mentor Worldwide. The registered enrollment target is 576 participants.
The verdict
NCT00752258, a Phase 3 study, has completed, sponsored by Mentor Worldwide.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 576 participants
- Enrollment target
Study Summary
The overall purpose of this study is to evaluate the long-term safety of repeat treatment with an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines.
Interventions
- DRUG Mentor Purified Toxin Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 576 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00752258
The ClinicalTrials.gov registry entry for NCT00752258 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 576 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mentor Worldwide, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mentor Purified Toxin Botulinum Toxin Type A is the first listed.
NCT00752258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00752258 about?
NCT00752258 is a clinical study titled "A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows". The overall purpose of this study is to evaluate the long-term safety of repeat treatment with an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines.
What is the current status of trial NCT00752258?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 576 participants. The study started on 2008-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00752258?
The interventions under investigation include: Mentor Purified Toxin Botulinum Toxin Type A (DRUG).
Who is sponsoring clinical trial NCT00752258?
This trial is sponsored by Mentor Worldwide, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.